ReviewCells2020
Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- MCT4 deficiency suppresses tumor incidence and metastasis by downregulating IGF1 expression and enhancing anti-tumor immunity.Communications biology · 2026Article
- Nutrition, GH/IGF-1 signaling, and cancer.Endocrine-related cancer · 2024Review
- In Vivo Effects of a GHR Synthesis Inhibitor During Prolonged Treatment in Dogs.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Reporting a novel growth hormone receptor gene variant in an Iranian consanguineous pedigree with Laron syndrome: a case report.BMC endocrine disorders · 2023Article
- Effects of GHR Deficiency and Juvenile Hypoglycemia on Immune Cells of a Porcine Model for Laron Syndrome.Biomolecules · 2023Article
- Characteristic amino acid residues in the growth hormone receptor gene onmicroPublication biology · 2023Article
- Growth hormone receptor gene disruption.Vitamins and hormones · 2023Article
- Insulin-like growth factors and aging: lessons from Laron syndrome.Frontiers in endocrinology · 2023Review
- Identification of UDP-Glucuronosyltransferase 2B15 (UGT2B15) as a Target for IGF1 and Insulin Action.Cells · 2022Article
- Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.European journal of endocrinology · 2022Review
- The Multiple Faces of the GH/IGF Axis.Cells · 2022Article
- Hallmarks of cancer: The insulin-like growth factors perspective.Frontiers in oncology · 2022Review
- MicroRNA 132-3p Is Upregulated in Laron Syndrome Patients and Controls Longevity Gene Expression.International journal of molecular sciences · 2021Article
- [Diabetes mellitus and cancer: a system of insulin-like growth factors].Problemy endokrinologii · 2021Article
- Article
- Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports.Biomolecules · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laron syndrome (LS) is a rare genetic endocrinopathy that results from mutation of the growth hormone receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.